Closely-held Hummingbird Bioscience raised $19-million in a Series B financing round co-led by Mirae Asset Venture Investment and GNTech Venture Capital. Existing investors Heritas Capital and Seeds Capital also...
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...
BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...
BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...
Aldeyra Therapeutics (NASDAQ:ALDX) reported positive topline results from the first part of its adaptive Phase 3 trial of topical ocular reproxalap for the treatment of dry eye disease. Part 1 of the study assessed...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) Drs. Robert Foster, CEO; Daren Ure, CSO; Daniel Trepanier, SVP drug development; and Patrick Mayo, SVP clinical pharmacology have been appointed adjunct professors by the University...
iBio (NYSE AMERICAN:IBIO) joined a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI), a consortium of more than 100 partner organizations from industry...
Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...
Gerald Solensky, Jr. has resigned as CEO, chairman and a director of Zomedica Pharmaceuticals (NYSE American, TSXV:ZOM), effective immediately. He will continue as a consultant to the company’s operating...
William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...